{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:29:22Z","timestamp":1792704562472,"version":"4.5.0"},"reference-count":45,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,7,1]]},"abstract":"<jats:p>The myelodysplastic syndromes (MDSs) are a group of clonal hematopoietic stem-cell disorders characterized by ineffective hematopoiesis and dysplasia. A wide spectrum of genetic aberrations has been associated with MDS, including chromosomal translocations involving the NUP98 gene. Using a NUP98-HOXD13 fusion gene, we have developed a mouse model that faithfully recapitulates all of the key features of MDS, including peripheral blood cytopenias, bone marrow dysplasia, and apoptosis, and transformation to acute leukemia. The MDS that develops in NUP98-HOXD13 transgenic mice is uniformly fatal. Within 14 months, all of the mice died of either leukemic transformation or severe anemia and leucopenia as a result of progressive MDS. The NUP98-HOXD13 fusion gene inhibits megakaryocytic differentiation and increases apoptosis in the bone marrow, suggesting a mechanism leading to ineffective hematopoiesis in the presence of a hypercellular bone marrow. These mice provide an accurate preclinical model that can be used for the evaluation of MDS therapy and biology.<\/jats:p>","DOI":"10.1182\/blood-2004-12-4794","type":"journal-article","created":{"date-parts":[[2005,3,8]],"date-time":"2005-03-08T22:43:46Z","timestamp":1110321826000},"page":"287-295","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":205,"title":["NUP98-HOXD13 transgenic mice develop a highly penetrant, severe myelodysplastic syndrome that progresses to acute leukemia"],"prefix":"10.1182","volume":"106","author":[{"given":"Ying-Wei","family":"Lin","sequence":"first","affiliation":[{"name":"From the Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Slape","sequence":"additional","affiliation":[{"name":"From the Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Zhang","sequence":"additional","affiliation":[{"name":"From the Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter D.","family":"Aplan","sequence":"additional","affiliation":[{"name":"From the Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223363700400_REF1","doi-asserted-by":"crossref","unstructured":"Mufti G, List AF, Gore SD, Ho AY. Myelodysplastic syndrome. Hematology (Am Soc Hematol Educ Program). 2003: 176-199.","DOI":"10.1182\/asheducation-2003.1.176"},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Kurzrock R. Myelodysplastic syndrome overview. Semin Hematol. 2002;39: 18-25.","DOI":"10.1053\/shem.2002.35981"},{"key":"2020021223363700400_REF3","doi-asserted-by":"crossref","unstructured":"Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27: 95-120.","DOI":"10.1016\/S0145-2126(02)00098-X"},{"key":"2020021223363700400_REF4","doi-asserted-by":"crossref","unstructured":"Slape C, Aplan PD. The role of NUP98 gene fusions in hematologic malignancy. Leuk Lymphoma. 2004;45: 1341-1350.","DOI":"10.1080\/10428190310001659325"},{"key":"2020021223363700400_REF5","doi-asserted-by":"crossref","unstructured":"Nakamura T, Largaespada DA, Shaughnessy JD Jr, Jenkins NA, Copeland NG. Cooperative activation of Hoxa and Pbx1-related genes in murine myeloid leukaemias. Nat Genet. 1996;12: 149-153.","DOI":"10.1038\/ng0296-149"},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Nakamura T, Yamazaki Y, Hatano Y, Miura I. NUP98 is fused to PMX1 homeobox gene in human acute myelogenous leukemia with chromosome translocation t(1;11)(q23;p15). Blood. 1999;94: 741-747.","DOI":"10.1182\/blood.V94.2.741"},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Borrow J, Shearman AM, Stanton VP Jr, et al. The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet. 1996;12: 159-167.","DOI":"10.1038\/ng0296-159"},{"key":"2020021223363700400_REF8","unstructured":"Taketani T, Taki T, Shibuya N, et al. The HOXD11 gene is fused to the NUP98 gene in acute myeloid leukemia with t(2;11)(q31;p15). Cancer Res. 2002;62: 33-37."},{"key":"2020021223363700400_","unstructured":"Taketani T, Taki T, Shibuya N, Kikuchi A, Hanada R, Hayashi Y. Novel NUP98-HOXC11 fusion gene resulted from a chromosomal break within exon 1 of HOXC11 in acute myeloid leukemia with t(11; 12)(p15;q13). Cancer Res. 2002;62: 4571-4574."},{"key":"2020021223363700400_REF10","unstructured":"Raza-Egilmez SZ, Jani-Sait SN, Grossi M, Higgins MJ, Shows TB, Aplan PD. NUP98-HOXD13 gene fusion in therapy-related acute myelogenous leukemia. Cancer Res. 1998;58: 4269-4273."},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Panagopoulos I, Isaksson M, Billstrom R, Strombeck B, Mitelman F, Johansson B. Fusion of the NUP98 gene and the homeobox gene HOXC13 in acute myeloid leukemia with t(11;12)(p15;q13). Genes Chromosomes Cancer. 2003;36: 107-112.","DOI":"10.1002\/gcc.10139"},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Ahuja HG, Felix CA, Aplan PD. The t(11;20)(p15; q11) chromosomal translocation associated with therapy-related myelodysplastic syndrome results in an NUP98-TOP1 fusion. Blood. 1999;94: 3258-3261.","DOI":"10.1182\/blood.V94.9.3258"},{"key":"2020021223363700400_","unstructured":"Ahuja HG, Hong J, Aplan PD, Tcheurekdjian L, Forman SJ, Slovak ML. t(9;11)(p22;p15) in acute myeloid leukemia results in a fusion between NUP98 and the gene encoding transcriptional coactivators p52 and p75-lens epithelium-derived growth factor (LEDGF). Cancer Res. 2000;60: 6227-6229."},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Arai Y, Hosoda F, Kobayashi H, et al. The inv(11)(p15q22) chromosome translocation of de novo and therapy-related myeloid malignancies results in fusion of the nucleoporin gene, NUP98, with the putative RNA helicase gene, DDX10. Blood. 1997;89: 3936-3944.","DOI":"10.1182\/blood.V89.11.3936"},{"key":"2020021223363700400_REF15","doi-asserted-by":"crossref","unstructured":"Hussey DJ, Nicola M, Moore S, Peters GB, Dobrovic A. The (4;11)(q21;p15) translocation fuses the NUP98 and RAP1GDS1 genes and is recurrent in T-cell acute lymphocytic leukemia. Blood. 1999;94: 2072-2079.","DOI":"10.1182\/blood.V94.6.2072"},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Jaju RJ, Fidler C, Haas OA, et al. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35; p15.5) in de novo childhood acute myeloid leukemia. Blood. 2001;98: 1264-1267.","DOI":"10.1182\/blood.V98.4.1264"},{"key":"2020021223363700400_REF17","unstructured":"Lahortiga I, Vizmanos JL, Agirre X, et al. NUP98 is fused to adducin 3 in a patient with T-cell acute lymphoblastic leukemia and myeloid markers, with a new translocation t(10;11)(q25;p15). Cancer Res. 2003;63: 3079-3083."},{"key":"2020021223363700400_REF18","doi-asserted-by":"crossref","unstructured":"Rosati R, La Starza R, Veronese A, et al. NUP98 is fused to the NSD3 gene in acute myeloid leukemia associated with t(8;11)(p11.2;p15). Blood. 2002;99: 3857-3860.","DOI":"10.1182\/blood.V99.10.3857"},{"key":"2020021223363700400_REF19","doi-asserted-by":"crossref","unstructured":"Powers MA, Forbes DJ, Dahlberg JE, Lund E. The vertebrate GLFG nucleoporin, Nup98, is an essential component of multiple RNA export pathways. J Cell Biol. 1997;136: 241-250.","DOI":"10.1083\/jcb.136.2.241"},{"key":"2020021223363700400_REF20","doi-asserted-by":"crossref","unstructured":"Radu A, Moore MS, Blobel G. The peptide repeat domain of nucleoporin Nup98 functions as a docking site in transport across the nuclear pore complex. Cell. 1995;81: 215-222.","DOI":"10.1016\/0092-8674(95)90331-3"},{"key":"2020021223363700400_REF21","doi-asserted-by":"crossref","unstructured":"Bayliss R, Littlewood T, Strawn LA, Wente SR, Stewart M. GLFG and FxFG nucleoporins bind to overlapping sites on importin-beta. J Biol Chem. 2002;277: 50597-50606.","DOI":"10.1074\/jbc.M209037200"},{"key":"2020021223363700400_REF22","doi-asserted-by":"crossref","unstructured":"Ogilvy S, Elefanty AG, Visvader J, Bath ML, Harris AW, Adams JM. Transcriptional regulation of vav, a gene expressed throughout the hematopoietic compartment. Blood. 1998;91: 419-430.","DOI":"10.1182\/blood.V91.2.419"},{"key":"2020021223363700400_REF23","doi-asserted-by":"crossref","unstructured":"Ogilvy S, Metcalf D, Gibson L, Bath ML, Harris AW, Adams JM. Promoter elements of vav drive transgene expression in vivo throughout the hematopoietic compartment. Blood. 1999;94: 1855-1863.","DOI":"10.1182\/blood.V94.6.1855"},{"key":"2020021223363700400_REF24","doi-asserted-by":"crossref","unstructured":"Kogan SC, Ward JM, Anver MR, et al. Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice. Blood. 2002;100: 238-245.","DOI":"10.1182\/blood.V100.1.238"},{"key":"2020021223363700400_REF25","doi-asserted-by":"crossref","unstructured":"Morse HC III, Anver MR, Fredrickson TN, et al. Bethesda proposals for classification of lymphoid neoplasms in mice. Blood. 2002;100: 246-258.","DOI":"10.1182\/blood.V100.1.246"},{"key":"2020021223363700400_REF26","doi-asserted-by":"crossref","unstructured":"Chervinsky DS, Zhao XF, Lam DH, Ellsworth M, Gross KW, Aplan PD. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Mol Cell Biol. 1999;19: 5025-5035.","DOI":"10.1128\/MCB.19.7.5025"},{"key":"2020021223363700400_REF27","unstructured":"Lerga A, Crespo P, Berciano M, et al. Regulation of c-Myc and Max in megakaryocytic and monocytic-macrophagic differentiation of K562 cells induced by protein kinase C modifiers: c-Myc is down-regulated but does not inhibit differentiation. Cell Growth Differ. 1999;10: 639-654."},{"key":"2020021223363700400_REF28","doi-asserted-by":"crossref","unstructured":"Goldfarb AN, Delehanty LL, Wang D, Racke FK, Hussaini IM. Stromal inhibition of megakaryocytic differentiation correlates with blockade of signaling by protein kinase C-epsilon and ERK\/MAPK. J Biol Chem. 2001;276: 29526-29530.","DOI":"10.1074\/jbc.M103825200"},{"key":"2020021223363700400_REF29","doi-asserted-by":"crossref","unstructured":"Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100: 2292-2302.","DOI":"10.1182\/blood-2002-04-1199"},{"key":"2020021223363700400_REF30","doi-asserted-by":"crossref","unstructured":"Howe RB, Porwit-MacDonald A, Wanat R, Tehranchi R, Hellstrom-Lindberg E. The WHO classification of MDS does make a difference. Blood. 2004;103: 3265-3270.","DOI":"10.1182\/blood-2003-06-2124"},{"key":"2020021223363700400_REF31","unstructured":"Dickstein JI, Vardiman JW. Hematopathologic findings in the myeloproliferative disorders. Semin Oncol. 1995;22: 355-373"},{"key":"2020021223363700400_REF32","doi-asserted-by":"crossref","unstructured":"Thiele J, Kvasnicka HM, Boeltken B, Zankovich R, Diehl V, Fischer R. Initial (prefibrotic) stages of idiopathic (primary) myelofibrosis (IMF)\u2014a clinicopathological study. Leukemia. 1999;13: 1741-1748","DOI":"10.1038\/sj.leu.2401553"},{"key":"2020021223363700400_REF33","doi-asserted-by":"crossref","unstructured":"Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, Sauvageau G. Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. EMBO J. 1998;17: 3714-3725.","DOI":"10.1093\/emboj\/17.13.3714"},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Lawrence HJ, Rozenfeld S, Cruz C, et al. Frequent co-expression of the HOXA9 and MEIS1 homeobox genes in human myeloid leukemias. Leukemia. 1999;13: 1993-1999.","DOI":"10.1038\/sj.leu.2401578"},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Shen WF, Rozenfeld S, Kwong A, Kom ves LG, Lawrence HJ, Largman C. HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells. Mol Cell Biol. 1999;19: 3051-3061.","DOI":"10.1128\/MCB.19.4.3051"},{"key":"2020021223363700400_REF36","doi-asserted-by":"crossref","unstructured":"Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol. 2001;21: 224-234.","DOI":"10.1128\/MCB.21.1.224-234.2001"},{"key":"2020021223363700400_REF37","doi-asserted-by":"crossref","unstructured":"Pineault N, Buske C, Feuring-Buske M, et al. Induction of acute myeloid leukemia in mice by the human leukemia-specific fusion gene NUP98-HOXD13 in concert with Meis1. Blood. 2003;101: 4529-4538.","DOI":"10.1182\/blood-2002-08-2484"},{"key":"2020021223363700400_REF38","unstructured":"Lam DH, Soloway PD, Tessarollo L, Aplan PD. inhibition of hematopoietic differentiation: a potential mechanism of leukemogenesis by the NUP98-HOXD13 fusion gene [abstract]. Blood. 2001;98: 836a."},{"key":"2020021223363700400_REF39","doi-asserted-by":"crossref","unstructured":"San Miguel JF, Hernandez JM, Gonzalez-Sarmiento R, et al. Acute leukemia after a primary myelodysplastic syndrome: immunophenotypic, genotypic, and clinical characteristics. Blood. 1991;78: 768-774.","DOI":"10.1182\/blood.V78.3.768.768"},{"key":"2020021223363700400_","doi-asserted-by":"crossref","unstructured":"Sato N, Nakazato T, Kizaki M, Ikeda Y, Okamoto S. Transformation of myelodysplastic syndrome to acute lymphoblastic leukemia: a case report and review of the literature. Int J Hematol. 2004;79: 147-151.","DOI":"10.1532\/IJH97.03137"},{"key":"2020021223363700400_REF41","doi-asserted-by":"crossref","unstructured":"Bonati A, Delia D, Starcich R. Progression of a myelodysplastic syndrome to pre-B acute lymphoblastic leukaemia with unusual phenotype. Br J Haematol. 1986;64: 487-491.","DOI":"10.1111\/j.1365-2141.1986.tb02204.x"},{"key":"2020021223363700400_REF42","doi-asserted-by":"crossref","unstructured":"Dash AB, Williams IR, Kutok JL, et al. A murine model of CML blast crisis induced by cooperation between BCR\/ABL and NUP98\/HOXA9. Proc Natl Acad Sci U S A. 2002;99: 7622-7627.","DOI":"10.1073\/pnas.102583199"},{"key":"2020021223363700400_REF43","doi-asserted-by":"crossref","unstructured":"Kroon E, Thorsteinsdottir U, Mayotte N, Nakamura T, Sauvageau G. NUP98-HOXA9 expression in hemopoietic stem cells induces chronic and acute myeloid leukemias in mice. EMBO J. 2001;20: 350-361.","DOI":"10.1093\/emboj\/20.3.350"},{"key":"2020021223363700400_REF44","doi-asserted-by":"crossref","unstructured":"Buonamici S, Li D, Chi Y, et al. EVI1 induces myelodysplastic syndrome in mice. J Clin Invest. 2004;114: 713-719.","DOI":"10.1172\/JCI21716"},{"key":"2020021223363700400_REF45","doi-asserted-by":"crossref","unstructured":"Moody JL, Xu L, Helgason CD, Jirik FR. Anemia, thrombocytopenia, leukocytosis, extramedullary hematopoiesis, and impaired progenitor function in Pten+\/-SHIP-\/- mice: a novel model of myelodysplasia. Blood. 2004;103: 4503-4510.","DOI":"10.1182\/blood-2003-09-3262"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/1\/287\/1710978\/zh801305000287.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/1\/287\/1710978\/zh801305000287.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T03:49:43Z","timestamp":1586144983000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/1\/287\/103188\/NUP98HOXD13-transgenic-mice-develop-a-highly"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,1]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-12-4794","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,1]]}}}